12:00 AM
 | 
Apr 15, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Tarafenacin: Phase IIb data

A double-blind, South Korean Phase IIb trial in 234 patients with OAB showed that once-daily 0.2 and 0.4 mg doses of oral tarafenacin were both "superior" to placebo in reducing the number of micturitions per day from baseline...

Read the full 166 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >